Skip to content
    REGN
    Earnings call· Mar 2025(Q1 FY25)

    REGENERON PHARMACEUTICALS, INC. REGN

    Apr 29, 2025 Source

    Executive summary

    Regeneron Q1 FY25 — Mixed Performance with EYLEA Headwinds Offset by Dupixent Growth and Pipeline Progress

    Regeneron reported a mixed Q1 FY25, with strong growth from Dupixent and Libtayo, and significant pipeline advancements, largely offset by substantial declines in EYLEA U.S. net sales. The company faced regulatory setbacks with a CRL for the EYLEA HD pre-filled syringe and continued competitive pressures in the anti-VEGF market, exacerbated by patient affordability issues. Despite these challenges, Regeneron continues to invest heavily in R&D and expects multiple regulatory approvals and data readouts later in 2025, while also returning capital to shareholders.

    Highlights

    5
    • Dupixent global net sales grew 20% YoY on a constant currency basis to $3.7 billion.

    • EYLEA HD U.S. net sales grew 54% YoY to $307 million, maintaining market leadership with EYLEA.

    • Libtayo global net sales grew 8% YoY on a constant currency basis to $285 million, with U.S. sales up 21%.

    • Four regulatory approvals and nine regulatory submissions achieved so far this year across the pipeline.

    • Free cash flow generated $816 million in Q1 FY25.

    Concerns

    4
    • EYLEA U.S. net sales were $736 million, down 39% YoY and 38% QoQ, due to lower wholesale inventory, competitive pressures, and increased usage of low-cost off-label Avastin.

    • FDA issued a Complete Response Letter (CRL) for the EYLEA HD pre-filled syringe, citing an issue with a third-party component supplier.

    • Combined U.S. net sales for EYLEA HD and EYLEA were $1.04 billion, down 30% sequentially, primarily due to lower wholesaler inventory levels and competitive pressures.

    • Dupixent U.S. net price was unfavorably impacted by the annual reset of commercial insurance deductibles and Medicare Part D redesign.

    Guidance & targets

    16
    CategoryTargetConfidence
    Full-year gross margin
    86% to 87%
    medium materiality
    High
    U.S. regulatory approvals
    linvoseltamab in relapsed/refractory multiple myeloma
    high materiality
    High
    U.S. regulatory approvals
    odronextamab in late-line follicular lymphoma
    high materiality
    High
    U.S. regulatory approvals
    Libtayo in adjuvant CSCC
    high materiality
    High
    U.S. regulatory approvals
    Dupixent in bullous pemphigoid
    high materiality
    High
    U.S. regulatory approvals
    differentiated enhancements to the EYLEA HD U.S. label
    high materiality
    High
    Pipeline data readouts
    pivotal or proof-of-concept data across programs in immunology, oncology, hematology, internal medicine and rare diseases
    high materiality
    High
    PDUFA date for Dupixent
    June 20
    high materiality
    High
    PDUFA date for linvoseltamab
    July 10
    high materiality
    High
    PDUFA date for odronextamab
    July 30
    high materiality
    High
    itepekimab pivotal readout
    data expected
    high materiality
    High
    fianlimab + Libtayo Phase III trial readout
    read out
    high materiality
    High
    trevogrumab Phase II COURAGE study data
    report data for 26-week primary endpoints
    medium materiality
    High
    C5 siRNA and antibody combination pivotal results
    expected
    high materiality
    High
    fianlimab + Libtayo Phase II studies next analysis
    expected
    medium materiality
    High
    FDA approvals for EYLEA HD
    retinal vein occlusion and for every 4-week dosing across all approved indications
    high materiality
    High

    Segment performance

    8
    SegmentRevenueYoYQoQMargin
    EYLEA (U.S.)
    Impacted by lower wholesale inventory levels, competitive pressures, and increased usage of low-cost off-label repackaged Avastin due to patient affordability issues.
    Physician unit demand: decreased by 14% sequentiallyWholesale inventory levels: ended in normal range
    $736 milliondown 39%down 38%
    EYLEA HD (U.S.)
    Growth offset by modest wholesaler inventory jot down. Potential for label enhancements (RVO, 4-week dosing) and pre-filled syringe approval to accelerate demand.
    Physician unit demand: grew by 5% sequentiallyWholesale inventory levels: modest jot down
    $307 millionup 54%flat sequentially
    EYLEA & EYLEA HD (U.S. Combined)
    Combined sales primarily reflected lower wholesaler inventory levels for both products and continued competitive pressures, exacerbated by a funding gap at patient assistance foundations.
    Physician unit demand (aggregate): declined by 11% sequentiallyAnti-VEGF category share: 41% (maintaining market leadership)Off-label repackaged Avastin share: increased by 6 percentage points to 32%
    $1.04 billiondown 30% sequentially
    EYLEA & EYLEA 8 mg (Outside U.S. - Bayer Collaboration)
    Includes sales of EYLEA 8 mg.
    EYLEA 8 mg sales: $146 million
    $858 millionup 5% constant currency
    Dupixent (Global)
    Reflecting strong growth across all approved indications, age groups, and geographic regions.
    $3.7 billion20% constant currency
    Dupixent (U.S.)
    U.S. net price unfavorably impacted by annual reset of commercial insurance deductibles and Medicare Part D redesign. Strong demand across all approved indications.
    New-to-brand prescription share: leads across all approved indications (except CSU)Total prescription share: leads across all approved indications (except CSU)COPD launch: outperformed all other Dupixent indication launches in cumulative new-to-brand prescriptions (except atopic dermatitis)
    $2.6 billion19%
    Libtayo (Global)
    Reflects typical seasonality dynamics and timing of shipments and lower inventory levels.
    $285 million8% constant currency
    Libtayo (U.S.)
    Demand continues to increase across non-melanoma skin cancer and lung cancer indications.
    Non-melanoma skin cancer indications: demand continues to increaseLung cancer market: share continues to increaseFirst-line advanced non-small cell lung cancer: second in new-to-brand prescription share
    $193 millionup 21%

    Operational metrics

    16
    Sanofi collaboration revenue
    $1.2 billion
    Q1 FY25

    Driven by Dupixent growth and higher U.S. net sales of EYLEA HD compared to the prior year.

    Sanofi collaboration profit share growth
    27%YoY
    Q1 FY25

    Driven by volume growth for Dupixent and higher collaboration margins.

    Sanofi development balance
    $1.5 billionreduction of approximately $180 million from end of 2024
    Q1 FY25

    Balance at the end of the first quarter.

    Bayer collaboration revenue
    $344 million
    Q1 FY25

    Related to share of net profits outside the U.S.

    R&D expense
    $1.2 billionModest growth versus prior year
    Q1 FY25

    Driven by continued investments to support innovative pipeline, including higher personnel expenses and clinical manufacturing costs.

    SG&A expense
    $537 milliondown 8% from prior year
    Q1 FY25

    Decline driven by lower general and administrative expenses.

    Gross margin on net product sales
    85%Lower versus prior year
    Q1 FY25

    Lower gross margin versus the prior year reflects higher inventory write-offs in the first quarter of 2025 and a changing product mix.

    Effective tax rate
    increased versus prior year
    Q1 FY25

    Primarily driven by a lower benefit from stock-based compensation deductions.

    Cash and marketable securities
    $17.6 billion
    Q1 FY25

    Ended the quarter with cash and marketable securities.

    Debt
    $2.7 billion
    Q1 FY25

    Approximately $2.7 billion in debt.

    Share repurchases executed
    $1.1 billion
    Q1 FY25

    Repurchased worth of shares in the first quarter.

    Remaining share repurchase authorization
    $3.9 billion
    Q1 FY25

    Remaining available for share repurchases.

    Quarterly dividend
    $0.88
    Q2 FY25

    Board of Directors declared the next dividend.

    Planned U.S. investments
    $7 billion
    multi-year

    These investments will enable us to continue to grow in the U.S. and support our differentiated R&D engine while significantly increasing our ability to manufacture both clinical and commercial supply.

    Patients with Chronic Spontaneous Urticaria (CSU)
    300,000
    current

    Estimate of patients in the U.S. with disease inadequately controlled by antihistamines.

    Adults with Bullous Pemphigoid
    30,000
    current

    Suffer from this difficult-to-treat condition.

    Industry KPIs

    3
    MetricValueDetails
    Therapeutic drug market share41%%
    Clinical trial efficacy safety data68% reduction%
    Collaboration milestone royalty revenue$1.2 billionUSD

    Product announcements

    3
    ProductTypeDetails
    Dupixentlaunch
    Dupixentmilestone
    Lynozyfic (linvoseltamab)milestone

    Deals & partnerships

    1
    FUJIFILM Diosynth BiotechnologiesNew agreement to invest over $3 billion to nearly double U.S. large-scale manufacturing capacity in North Carolina.over $3 billion

    This agreement, along with our $3.6 billion expansion of our Tarrytown, New York R&D and preclinical manufacturing facilities, our fill/finish facility in Rensselaer, New York and the acquisition of an additional property in Saratoga Springs, New York, represent planned U.S. investments of over $7 billion.

    Risks & headwinds

    6
    Significant decline in EYLEA U.S. net salesQ1 FY25

    down 39% YoY and 38% QoQ to $736 million

    Mitigation: Focus on promoting EYLEA HD adoption; exploring matching program for patient assistance foundations.

    FDA Complete Response Letter for EYLEA HD pre-filled syringeQ1 FY25

    CRL issued

    Mitigation: Engaging with FDA to understand and resolve the key outstanding issue related to a third-party component supplier; supplier has expeditiously responded to FDA requests.

    Increased usage of low-cost off-label repackaged Avastin and competitive pressures in the anti-VEGF categoryQ1 FY25

    Avastin share increased by approximately 6 percentage points to 32%

    Mitigation: Promoting EYLEA HD as potential new standard of care; seeking label enhancements for EYLEA HD; exploring matching program for patient assistance foundations to address affordability.

    Unfavorable impact on Dupixent U.S. net priceQ1 FY25

    unfavorably impacted

    Mitigation: Not explicitly stated, but continued strong demand and market leadership across indications.

    Potential impact from sector-specific tariffsongoing

    not quantifiable at this time

    Mitigation: Committed to making significant investments in the United States to expand R&D and manufacturing capabilities (over $7 billion planned U.S. investments).

    Increased FDA scrutiny on contract manufacturers leading to regulatory delays (CRLs)past 12 months

    multiple CRLs related to third-party suppliers

    Mitigation: Working closely with suppliers and FDA to resolve issues; acknowledging the broader industry trend of increased scrutiny.

    What to watch in Q2 FY25

    5

    EYLEA HD Pre-filled Syringe Approval

    Coming weeks or months
    CurrentCRL issued
    TargetApproval

    Why it matters

    Resolution of this issue is important for EYLEA HD's market adoption and ease of administration, potentially accelerating demand.

    We'll know more in the coming weeks or months, and we will hopefully💬 get it across the finish line in a short while, but we'll try and keep you posted once we know what the FDA is really up to.

    Q&A highlights

    6

    Elaborate on the FDA's question regarding the component supplier and compare the situation to the previous EYLEA HD CRL resolution timeline.

    Len Schleifer explained that the CRL relates to a third-party component supplier's drug master file (DMF), where the FDA interacts directly with the supplier. Regeneron is not privy to the details but believes one key issue remains, which the supplier has expeditiously addressed. He noted the same device is approved in Europe. The resolution timeline is uncertain but could be quick, similar to the prior CRL, as no reinspection is involved.

    We believe that there's one key issue that is left to resolve. There are a few other minor ones, which I think were just clarifications. But the one key issue relates to a supplier and the supplier has told us that the FDA asked for some data. They have all the data. They expeditiously supplied it.

    asked by Tyler Van Buren · answered by Leonard Schleifer

    3 min read7 chapters

    Detailed Narrative

    01

    EYLEA and EYLEA HD Performance and Challenges

    EYLEA U.S. net sales declined significantly to $736 million, down 39% YoY and 38% QoQ, due to lower wholesale inventory, competitive pressures, and increased use of low-cost off-label Avastin. This shift was driven by patient affordability issues and a funding gap at co-pay assistance foundations. EYLEA HD showed strong year-over-year growth of 54% to $307 million but was flat sequentially, also impacted by inventory adjustments. Combined, EYLEA and EYLEA HD captured 41% of the anti-VEGF category, maintaining market leadership despite these headwinds.

    02

    Regulatory Setback for EYLEA HD Pre-filled Syringe

    The FDA issued a Complete Response Letter (CRL) for the EYLEA HD pre-filled syringe, primarily due to a question posed to a third-party component supplier regarding a drug master file. Management believes the issue is resolvable and does not relate to safety, efficacy, usability, labeling, or inspection findings, noting the same device is approved and safely used in Europe. The company is engaging with the FDA and the supplier to expedite resolution, though the timeline remains uncertain.

    03

    Dupixent's Continued Growth and New Indications

    Dupixent demonstrated robust global sales growth of 20% (constant currency) to $3.7 billion, driven by strong demand across approved indications and geographic regions. It achieved its seventh FDA approval for chronic spontaneous urticaria (CSU) and became the first biologic approved for COPD in Japan. The U.S. COPD launch is gaining momentum with increasing prescriber appreciation and favorable payer coverage, outperforming all other Dupixent indication launches in cumulative new-to-brand prescriptions, except atopic dermatitis.

    04

    Libtayo's Expanding Market Share

    Libtayo continued to grow, with global net sales up 8% (constant currency) to $285 million and U.S. sales up 21% to $193 million. It has established itself as a cornerstone therapy for advanced non-melanoma skin cancer and is increasing its share in the lung cancer market. Libtayo is now second in new-to-brand prescription share in first-line advanced non-small cell lung cancer, reflecting its differentiated clinical profile and commercial strategy.

    05

    Oncology Pipeline Advancements

    Regeneron's oncology pipeline saw significant progress with conditional marketing authorization for linvoseltamab in Europe and accepted BLA resubmissions for linvoseltamab (multiple myeloma) and odronextamab (follicular lymphoma) in the U.S., both with PDUFA dates in July. Data for Libtayo in adjuvant CSCC, showing a 68% reduction in recurrence risk, will be presented at ASCO. A Phase III trial for Libtayo + fianlimab in metastatic melanoma is expected to read out in H2 2025, with early data suggesting substantial additive benefit.

    06

    Broader Pipeline Progress

    Beyond oncology, the company is advancing its Factor XI program, with pivotal studies enrolling this year, investigating two different antibodies for improved blood clot prevention and lower bleeding risk. The Phase II COURAGE study for trevogrumab in obesity, aiming to improve weight loss quality by maintaining muscle mass, is expected to report data in H2 2025. Pivotal results for the C5 siRNA/antibody combination in generalized myasthenia gravis are also anticipated in H2 2025, building on strong C5 inhibition data in PNH.

    07

    Strategic Investments and Capital Allocation

    Regeneron announced over $7 billion in planned U.S. investments to expand R&D and manufacturing capacity, including a new $3 billion agreement with FUJIFILM Diosynth Biotechnologies and a $3.6 billion expansion of its Tarrytown facilities. These investments aim to support U.S. growth and manufacturing capabilities. The company also returned capital to shareholders, repurchasing $1.1 billion worth of shares in Q1 and initiating a quarterly dividend of $0.88 per share.

    AI-generated summary of the company’s earnings call. Not investment advice.